Study of High dose Toremifene for metastatic breast cancer after failure of adjuvant therapy of Aromatase Inhibitor
Phase 2
- Conditions
- First line therapy for recurrence or metastatic postmenopausal breast cancer
- Registration Number
- JPRN-UMIN000000489
- Lead Sponsor
- agoya University of School of Medicine Breast and Endocrine Surgery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1.brain metastasis 2.bilateral brest cancer 3.male breast cancer 4.severe allergy 5.severe complications
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response Rate
- Secondary Outcome Measures
Name Time Method Clinical benefit, Progression-Free Survival, adverse events